M&A

News

Roche snaps up ex-US rights to Sarepta's DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal.

Views & Analysis

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

News

BMS files first drug from triple bet with Celgene shareholde...

Bristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” with former investors in Celgene that could pay out billions if they all successfully make i

News

Could Spark Therapeutics’ merger with Roche finally get the ...

Spark Therapeutics’ merger with Roche has moved a step closer after the UK’s competition watchdog okayed the $4.8 billion deal, ahead of a regulatory deadline later today in the US.

News